In this study, we identified that LINC01852 is significantly downregulated in CRC and inhibits CRC cell proliferation, glycolysis, and chemoresistance by promoting TRIM72-mediated SRSF5 degradation and suppressing the alternative splicing of PKM2 (Fig. 8I). This evidence concerns the gene LINC01852 and colorectal carcinoma.